Podcasts about CRS

Jacques Witkowski, préfet du Bas-Rhin, sur le départ. Ce dernier devrait être nommé aujourd'hui pour prendre la tête de la préfecture des Bouches-du-Rhône et de la région Paca. L'annonce officielle devrait être faite à l'issue du Conseil des ministres, ce matin. Jacques Witkowski, qui endosserait aussi le rôle de préfet de police de Marseille, aurait été choisi pour sa carrure et son CV, dans l'objectif de lutter contre le narcotrafic. Pas de grand changement pour le dispositif de sécurité du marché de Noël de Strasbourg. Les grandes lignes du plan mis en place l'année dernière seront reprises pour cette nouvelle édition, qui va débuter le mercredi 26 novembre. Pour limiter les flux, l'accès à la cathédrale sera modifié. Son entrée sera située place du château. Plusieurs rues piétonnes auront un sens unique et des mesures exceptionnelles seront mises en place en cas de trop grande affluence. Plus de 1 000 policiers, gendarmes et CRS seront aussi mobilisés chaque jour. Des contrôles aléatoires des piétons et des cyclistes seront encore effectués sur les ponts d'accès. Des sacs à pain pour lutter contre les violences. A l'occasion de la journée du 25 novembre, journée internationale de lutte contre les violences faites aux femmes, les services de l'Etat dans le Haut-Rhin lancent une action de prévention. Dès demain, 50 000 sacs à pain seront distribués dans une centaine de boulangeries du département, avec des informations pratiques consacrées à la lutte contre les violences intrafamiliales. Une action de prévention qui vise notamment à faire connaître le numéro national, 39 19. Faits divers. Deux jeunes ont été interpellés en ce début de semaine au lycée André-Siegfried de Haguenau. La police est intervenue après une alerte de l'établissement, qui déplorait des menaces de mort filmées et envoyées à un élève de 15 ans. Originaire de Souffelweyersheim, l'auteur de ces propos n'est pas scolarisé dans ce lycée, contrairement à son complice qui a filmé et partagé les faits. Lors de son interpellation, ce dernier était aussi en possession d'un couteau. Deux magasins Leclerc ont été victimes de cambriolage dans le Haut-Rhin. Ce week-end, c'est l'enseigne de Wintzenheim qui a été touchée, l'alarme s'était déclenché vers 3h40 mais les cambrioleurs avaient réussi à fuir avant l'arrivée des forces de l'ordre. Deux jours plus tard, dans la nuit de lundi, les salariés du Leclerc de Cernay ont découvert les traces d'un cambriolage principalement dans l'espace culturel. Ils ont notamment constaté des vols de téléphones et d'éléments multimédias. Un préjudice qui pourrait atteindre plusieurs dizaines de milliers d'euros.Et attention sur la route, la liaison entre Saint-Pierre et Eichhoffen sera prochainement fermée. Cette dernière sera inaccessible jeudi et vendredi, à partir de la fin de journée et pour une bonne partie de la nuit. Une décision prise pour les besoins du tournage de la série Vice-Versa, qui sera diffusée sur France 2. Des scènes seront tournées au château d'Ittenwiller, mais aussi sur la route départementale D98. Une déviation sera mise en place. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

This episode of our "AI in Real Estate" series features real estate expert Vandana Bhalla, CRS, who takes us inside her journey of integrating AI into her business. From automating repetitive tasks to delivering more personalized client experiences, Vandana explains how agents can use AI to strengthen their sphere of influence and stay competitive in a changing market.

How do you decide between a best-in-class tech stack and an all-in-one platform?I caught up with Bill Fanning, CRO of Stayntouch, and Klaus Kohlmayr, Chief Evangelist at IDeaS Revenue Solutions, to discuss the new NYU SPS Tisch Center of Hospitality Technology Report, where 300+ hoteliers shared how they're making those crucial tech decisions. On hashtag#NoVacancyNews, we look at what's driving those hashtag#hoteltechnology choices, the cultural and operational challenges behind switching systems, and why more hotels than ever plan to replace their tech stack within the next 24 months. Key Insights:

Dans cette édition :Retour à Molenbeek, la commune de Bruxelles où s'était réfugié Salah Abdeslam, le terroriste des attentats du 13 novembre 2015, à la veille des commémorations de ces événements tragiques.Témoignages de riverains sur la présence encore palpable de l'islamisme radical et du trafic de drogue dans ce quartier.Indignation du ministre de la Justice Gérald Darmanin face aux conditions de détention de Salah Abdeslam, qui a eu accès à un ordinateur portable et une clé USB en prison.Emmanuel Macron relance les grands débats citoyens, mais fait face à des électeurs déçus par sa politique, notamment sur la réforme des retraites.Mort d'un adolescent de 16 ans à Tourcoing après un refus d'obtempérer, entraînant le déploiement de CRS.Cauchemar de deux propriétaires victimes de squatteurs depuis près de trois ans à Aubagne, qui peinent à récupérer leurs appartements.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Des agriculteurs convergent en tracteur vers Toulouse pour manifester contre les déclarations d'Emmanuel Macron sur le Mercosur, et pourraient être reçus par le président en visite dans la ville.Les députés reprennent les débats sur le budget de la Sécurité sociale, avec l'examen prioritaire de l'article suspendant la réforme des retraites, une mesure qui aura un coût important dans les années à venir.Marion Maréchal estime que l'État n'a pas su adapter son arsenal législatif et judiciaire face à la menace terroriste, et s'interroge sur la volonté de Salah Abdeslam d'ouvrir une porte au parti civil dans une démarche de justice restaurative.Un jeune de 16 ans est décédé à Tourcoing après un refus d'obtempérer, entraînant l'envoi de renforts de CRS.Les autorités israéliennes annoncent l'ouverture permanente du point de passage de Zikim au nord de Gaza pour acheminer de l'aide.42 personnes sont présumées mortes après le naufrage d'une embarcation transportant des migrants au large des côtes libyennes.Le tennisman Carlos Alcaraz est bien parti pour rester numéro 1 mondial jusqu'en début d'année prochaine.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Retour à Molenbeek, la commune de Bruxelles où s'était réfugié Salah Abdeslam, le terroriste des attentats du 13 novembre 2015, à la veille des commémorations de ces événements tragiques.Témoignages de riverains sur la présence encore palpable de l'islamisme radical et du trafic de drogue dans ce quartier.Indignation du ministre de la Justice Gérald Darmanin face aux conditions de détention de Salah Abdeslam, qui a eu accès à un ordinateur portable et une clé USB en prison.Emmanuel Macron relance les grands débats citoyens, mais fait face à des électeurs déçus par sa politique, notamment sur la réforme des retraites.Mort d'un adolescent de 16 ans à Tourcoing après un refus d'obtempérer, entraînant le déploiement de CRS.Cauchemar de deux propriétaires victimes de squatteurs depuis près de trois ans à Aubagne, qui peinent à récupérer leurs appartements.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Des agriculteurs convergent en tracteur vers Toulouse pour manifester contre les déclarations d'Emmanuel Macron sur le Mercosur, et pourraient être reçus par le président en visite dans la ville.Les députés reprennent les débats sur le budget de la Sécurité sociale, avec l'examen prioritaire de l'article suspendant la réforme des retraites, une mesure qui aura un coût important dans les années à venir.Marion Maréchal estime que l'État n'a pas su adapter son arsenal législatif et judiciaire face à la menace terroriste, et s'interroge sur la volonté de Salah Abdeslam d'ouvrir une porte au parti civil dans une démarche de justice restaurative.Un jeune de 16 ans est décédé à Tourcoing après un refus d'obtempérer, entraînant l'envoi de renforts de CRS.Les autorités israéliennes annoncent l'ouverture permanente du point de passage de Zikim au nord de Gaza pour acheminer de l'aide.42 personnes sont présumées mortes après le naufrage d'une embarcation transportant des migrants au large des côtes libyennes.Le tennisman Carlos Alcaraz est bien parti pour rester numéro 1 mondial jusqu'en début d'année prochaine.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

hVIVO PLC (AIM:HVO) chief scientific officer Andrew Catchpole talked with Proactive about the company's latest developments in human challenge models across multiple viral pathogens. Catchpole explained that hVIVO presented new data at the European Scientific Working Group on Influenza (ESWI) and the World Vaccine Congress, highlighting the role of challenge models in expediting vaccine and antiviral development. “Challenge models give a really good opportunity to get fast proof of concept data very, very quickly,” he said. He detailed progress on several new models, including those for RSV B, HMPV, and Omicron. The HMPV model addresses a critical unmet medical need, as there are currently no approved treatments or vaccines. Catchpole said the model supports fast-tracked development of interventions for at-risk populations such as infants and the elderly. The finalised Omicron challenge model reflects real-world conditions, targeting vaccinated or previously exposed individuals. This enables the evaluation of next-generation or pan-coronavirus vaccines. Catchpole also outlined how the RSV B model complements existing RSV A research, particularly for assessing combination vaccines across both strains. These models can serve both early-stage proof of concept and as supplementary data to traditional phase 2 or 3 studies. Looking ahead, hVIVO is expanding into respiratory conditions like asthma and COPD, and through its acquisition of CRS, is moving into cardiometabolic and renal disease models. The company is also extending its lab capabilities with next-generation sequencing and digital PCR tools. Visit Proactive's YouTube channel for more interviews like this. Don't forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #hVIVO #AndrewCatchpole #RSV #HMPV #Omicron #ChallengeModels #VaccineDevelopment #AntiviralResearch #ClinicalTrials #ProactiveInvestors #PharmaNews #BiotechUpdates #InfectiousDiseaseResearch

How can carbon finance do more to strengthen rural livelihoods and empower the communities on the frontlines of climate change? Social Impact Pioneers - Anna Kilpatrick, from PUR, Ann Vaughan & Lilian Gwazayo of CARE, and Olaf Westermann, from Catholic Relief Services (CRS) explore this critical question. The conversation, in turn, hears from people implementing carbon finance programmes with a focus on deepening livelihood benefits in countries from around the world, including Mr. Matola Sigele in Malawi; Karimi in Cambodia; Emmanuel and Joshua in Uganda. Together, they unpack how nature-based solutions, carbon markets, and community-led restoration can deliver climate impact rooted in equity and sustainability. The conversation dives into payment for ecosystem services, carbon equity, and the importance of long-term investment in communities that steward forests and farmlands. You will hear how carbon projects are reshaping livelihoods—improving food security, empowering women, and restoring degraded landscapes. And also some of the challenges - in making these programmes work - whether land rights, short-term rewards, or understandable skepticism. This episode offers practical insights for businesses, investors, and NGOs seeking to align carbon finance integrity with inclusive development. Listen now to explore how climate finance can be a cornerstone of sustainable livelihoods—not just a co-benefit. This conversation is hosted by Yvette Torres-Rahman, co-founder of Business Fights Poverty. Social Impact Pioneers: - Anna Kilpatrick, Chief Strategy and Impact Officer at PUR, whose agroforestry projects help global companies decarbonize agricultural supply chains while improving smallholder incomes. - Ann Vaughan, Associate Vice President for Resilient Futures at CARE, leading work to unlock climate finance that reaches 25 million people, especially women and girls. - Olaf Westermann, Senior Technical Advisor on Climate Change and Agriculture at CRS, connecting conservation, livelihoods, and equity in nature-based carbon projects worldwide. - Lilian Gwazayo, Field Advisor, & Environmental Scientist, CARE, Malawi. Links: Redd+ Projects: https://unfccc.int/topics/land-use/workstreams/redd/what-is-redd PUR: https://www.pur.co/ Catholic Relief Services: https://www.crs.org/ Care: Malawi We Staan Nog Steeds: https://www.carenederland.org/verhaal/malawi-we-staan-nog-steeds Care: Malawi: Herstel van groene vegetatie draagt bij aan duurzame toekomst https://www.carenederland.org/nieuws/malawi-het-herstellen-van-groene-vegetatie CARE Malawi LinkedIn: https://www.linkedin.com/company/care-international-in-malawi/posts/?feedView=all CARE Nederland: https://www.linkedin.com/company/care-nederland/posts/?feedView=all Restore Africa: https://www.evergreening.org/restoreafrica/

In this episode of Manager Minute, host Carol Pankow welcomes Dr. Chaz Compton and Dr. Meera Adya, co-directors of the new National Vocational Rehabilitation Technical Assistance Center (NVRTAC). They discuss how the Center builds on decades of innovation in vocational rehabilitation (VR) to unify training, evaluation, and technology that strengthen state VR agencies across the nation. Partnering with The George Washington University, the National Disability Institute, CSAVR, YesLMS, Case Review Solutions, SaraWorks, and Intellitech, the NVRTAC delivers comprehensive technical assistance to enhance performance, fiscal management, and employment outcomes for individuals with disabilities. Key initiatives include AI-driven tools such as SaraWorks and Case Amplify, designed to reduce administrative burdens and capture real-world impact. The team is also launching leadership and fiscal talent development programs, expanding recruitment and retention efforts, and embedding continuous evaluation across all initiatives. Their goal is to achieve measurable outcomes, real change, and a stronger, more efficient VR system serving individuals with disabilities.   Listen Here   Full Transcript:   {Music} Chaz: Right now, not ten years from now, but right today, we have the capacity to. Turn our administrative burden into an AI driven function that alleviates that burden.   Meera: Input is getting provided at the beginning and the middle at the end all over again. It really is that measurable and real change and ongoing calibration towards that is our North star.   Chaz: And having actual measurable outcome improvements. So simple as that.   Carol: That sounds good. How about you? What do you think?   Meera: Nothing to add. Measurable outcomes. Real change. Drop the mic.   Carol: Boom! I love it.   {Music} Intro Voice: Manager Minute, brought to you by the Vocational Rehabilitation Technical Assistance Center. Conversations powered by VR. One manager at a time, one minute at a time. Here is your host, Carol Pankow.   Carol: Well, welcome to the Manager Minute. Joining me in the studio today are my close colleagues, doctor Chaz Compton and Doctor Meera Adya, Co-project directors of the new National Vocational Rehabilitation Technical Assistance Center, or VRTAC for short. So woohoo you guys! I'm so excited to have you here. How are things going Chaz?   Chaz: Wonderful. Very busy and very happy to be here. Thank you.   Carol: Excellent. How about you, Meera? How's it going?   Meera: Pretty good.   Carol: Awesome. Well, glad to have you both. I just want to give a little bit of history for our listeners. The Vocational Rehabilitation Technical Assistance Centers have a long and rich history rooted in the Rehabilitation Act itself. And from the very beginning, the act recognized that helping individuals with disabilities achieve meaningful employment requires more than just funding. It requires a system of continuous learning, innovation and improvement. And that's why the Rehabilitation Services Administration has long invested in national technical assistance centers to strengthen state VR agencies, build staff capacity and ensure programs stay aligned with evolving regulations, Relations, research and best practices, and over the years, these centers from the early TACE centers to WINTAC and the QM and QE and AIVR TAC and all the things, and now the new NBR tech have become the backbone of progress in our field, helping translate policy into practice and ensuring that the promise of the Rehabilitation Act remains strong for the next generation. So let's dig in. Gang, can you tell our listeners a little bit about yourselves and your journey into VR? And, Chaz, I'm going to kick it to you first.   Chaz: Okay. Gosh, it's been 40 years now. Hard to believe. I started with a community rehab program 40 years ago this year.   Carol: Wow.   Chaz: A few years later, I moved into the public VR program in California. I was a counselor, a supervisor, and then a district administrator and got my doctorate degree at San Diego State University and moved over and directed the TA Center 15 years ago, and then the WINTAC and then the VRTAC-QM and now the what we call the VR TAC, the national VRTAC.   Carol: That is awesome. I did not realize it was 40 whole years. Chaz, I think we're pretty close in age to each other.   Chaz: It's been a while.   Carol: Meera, how about you? How'd you get your journey into this world?   Meera: Well, my work has always been at the intersection of empiricism and law and policy. So I'm a researcher and evaluator. I've done projects looking at how people with disabilities can be successful in workplaces and communities, thinking about inter work and the VR system. More specifically, I became engaged first as a partner, leading the program evaluation for Interworks Wintech centre. And then Chaz convinced me to come to Interworks continue doing what I was doing by taking the lead on the program evaluation for the VR, QM, and then our portfolio at Interworks has grown. Now there are several disability innovation grants and customized employment projects in addition to the TAC that we are leading the evaluation on. And Chaz then offered me the opportunity to continue growing my work, and here I am as the co-director of the center as a whole, and I'm honored and thrilled to support Chaz and our team. Take the work with VR and its partners forward to improve outcomes for people with disabilities.   Carol: I love it Meera, and you're a good addition, and we're really happy to have you as the Co-project director, too. So what is the overarching purpose of our new VR TAC?   Chaz: It is to provide technical assistance and training that will help VR agencies and their partners improve service delivery and increase the quantity and quality of employment outcomes for individuals with disabilities being served by VR program and their partners. Our major focus areas include helping agencies effectively manage the program, the performance of the program, the fiscal side of the program and their resources, and helping them identify and implement effective employment strategies and practices that accomplish the overarching goal of helping improve outcomes and service delivery. That's the big picture.   Carol: It is cool because it's like soup to nuts. I think sometimes, you know, the previous TAC, you know, they had very kind of more specific focus. And then with the QM and like QE too, you know, it expanded. But now we've got the whole shebang in one place.   Chaz: Mhm.   Carol: Very fun. Meera do you have anything you wanted to add to that?   Meera: Sure. I was just thinking about all the work that Chaz has been doing, the messages he sends us and how we've come together and so far trying to put it into an encapsulation. I've been coming up with one team or his words, but I think just such a good representation and you'll see that now in our messaging going forward, but also a yes. And we don't say no. We find a way to work together and is so what, what is the measurable change that's going to result from the work we do? I think you're going to see that over the next five years constantly coming up.   Carol: Yeah, I like that, Meera. You got to keep us grounded in that. About the so what? So what we can do lots of activities. But so what about them? And I see, Chaz, you're smiling at me because, you know, I'm an activity person. And it's like, but what's the benefit from what we did? So how does the new TAC build on the work in the lessons that were learned from all the previous work?   Chaz: Well, to say we've learned some lessons along the way, especially in the last ten years, would be an understatement. There have been the implementation of WIOA and all of the requirements associated with that, living through all of the implementation with agencies, helping them respond to that effectively, looking at the demographic shift in the field to youth, where now the majority of the people we serve are 24 years of age or younger. Looking at going into and out of Covid and how that changed service delivery, how the fiscal landscape of the program changed accordingly, how we have seen the pendulum shift fiscally from one side to the other and now back again. All of that has helped inform, I think, the development of our technical assistance and the training and the way we go into this new center. So we have just a bunch of lived experience, if you will, along with agencies. So what they have gone through, we have gone through with them, and I think we can help them successfully navigate the future. And while at the same time responding to the challenges that they face right now. So all of that, I think, really has laid an important foundation for the VRTAC and the work we're going to be doing with agencies.   Carol: I think you hit the nail with that. I think about all the last five years, even the work I've done and our team has done and how deep we got in with agencies like it felt like we were part. I often talk when I'm in at agency, I talk about we like I'm part of them because you're enmeshed in everything they're doing and their systems and their people and their meetings and all of their things. You become so ingrained with them. It really helped you to get such a clear picture of what was happening and helps really get maybe at the root of some of the issues and to develop that work fundamentally so that the seeds we laid could really grow and germinate and keep going forever and keep growing and growing and growing. So it isn't just a one shot. We did a little quick training and we're out of there. It really became such a deep lesson. Meera, how about for you with that lessons learned? I'm sure evaluation wise there are things you were thinking about as well.   Meera: Oh, absolutely. We have all of our past evaluation reports and findings, and we can keep looking at those. And I certainly keep bringing them up whenever it strikes me that there's a relevant point that comes forward again. And you can see with the way that Chaz has put together these innovative partners and projects, a continuation of the successful approaches and partnerships as well, and just a laser focus on measurable change that evolution and improvement and lessons learned is just baked into the center. As a research and evaluator, I know firsthand how the knowledge translation pipeline takes time, but it can take less time when you work directly with stakeholders from the beginning, and that's what's happening with us. Chaz has always taken evaluation seriously, woven it into the very fabric of the work. Stakeholders are the partners. They hold us accountable. We continuously are learning what's working. Pivot when needs must.   Carol: Well said Meera. Thank you for that. What current challenges do you guys see in the VR system that make a unified national TA center so important right now?   Chaz: To say that efficiency, accountability and improved outcomes are important would be an understatement. And this is not a new focus, of course. I mean, you have to go back to the movement of the Rehabilitation Act under the Workforce Investment Act of 1988, which was really an attempt to improve efficiency and refrain from duplication of services and improve outcomes and all that stuff. And that focus has just grown and grown,   Carol: right.   Chaz: and so a unified center is I mean, it really is helpful to ensure that everything is administrated under one center that we're focused on, you know, whether it's focused on improving performance, like on the performance measures, like improving an agency's ability to manage their fiscal resources or implement employment strategies like, say, customized employment, a unified center can address all of these aspects together, holistically, understand how they interact with each other and an agency. Instead of having 2 or 3 different entities trying to work together with a VR program differently, with different ways of doing business, ways of interacting all that. So it just is a very efficient, I hope. Anyway, an enhanced holistic way of working with an agency. Ultimately, I believe that will contribute to increasing the likelihood of positive outcomes.   Carol: I like the part with the employment being in with us now. Not that employment wasn't in our mind, but it was distant because we'd always put it like we, you know, we're referring folks over to the Q2E, but now with it all integrated, it really does kind of front and center. You're thinking about the fiscal things that my group is working at and how our impact is helping the program, maybe for stability or whatever may be going on, does impact the employment outcomes in the end, and the funds that are available and whether people go on an order or not, you know, all those kind of things. So I like that having it all together, it's a little closer, at least in my head. Meera, did you have any thoughts about that one as well?   Meera: I echo everything you both have said. The unified voice. Central voice. This center has always been a supportive voice. It is always on, always available, and that continues to be really needed. That is something we've heard in the evaluation interviews and feedback that we've received is that folks really appreciate being able to just call, get someone on the other end, get an answer right away, send an email, hear back right away. The responsiveness and the targeted information that they need has been phenomenal. And so looking forward to that continuing. And now across the whole range and spectrum of what technical assistance is needed. As you both have said, It's a time of, you know, as was said, significant change requirements may be shifting again, a laser focus on efficiency and effectiveness of work, which is right. And, you know, in the broader context, we're seeing significant disruption in the work world. And the future of work has been talked about. The future of work is here today. It's the today of how we work. And agencies need help navigating all of that with their customers. There's a lot for our stakeholders and our partners to navigate. I think we've seen from the evaluation feedback, this is where our team under Chaz really excels. It just brings together the many. It brings together the a lot. It goes to the heart of it and meets it on the grant.   Carol: Yeah. You lead into my next question about the partners on the grant because we have a deep bench. I mean, I felt like we had really phenomenal folks on the QM grant. But when I look at the partners you all have brought together for this, and we're on our first meetings and you've got, you know, 30 people in the Hollywood Squares instead of a dozen or so. It's a cool bunch, and people with such interesting expertise. So Chaz, who are the partners on our grant?   Chaz: Our biggest and primary partner is the George Washington University. We've been partners with them for really since national centers were funded. They were part of the WINTAC, part of the QM, and now we'll be a obviously a critical part of the VR TAC Every single one of them is a doer. Their hands are have their hands have gotten dirty and providing like literally in the trenches to just like our own staff at work Institute at San Diego State. We just have been, practically speaking, teammates for a very long time. We know each other well, we work together well, and we're very confident in each other's work. GW a big, huge partner of ours. Then there's the National Disability Institute, which is also a longtime partner of ours. They'll be helping with the employment strategies component of things and just are a very well respected, nationally known institute that is really has some super interesting and helpful information and resources and knowledge along with the rest of the team. Of course, many of our listeners will know. Yes LMS, we're working with Linda and her team this time around, expanding our available training resources to users out there. CSAVR of course, is another long time partner. Everybody knows them. Sara Works is a partner of ours as well. Sara Works has been a partner again since the WINTAC days and, you know, has done all kinds of work with us in terms of developing Sara, the AI program to help act as an assistant to VR programs, communication tool and so on. Then we have Case Review Solutions. It's just a new partner of ours this time around focused on quality assurance, case reviews, contract monitoring. So another use of software and technology to basically provide solutions to VR programs. And another new partner this time around in Intellitech, which has created a program called Case Amplify, which is an AI driven system, which we'll talk about here in a few minutes, but we're really excited about this one as well, because it provides an opportunity for agencies to see how things could potentially be different and more effective into the future. So those are our primary partners, yeah.   Carol: yeah. It's exciting. It's a cool group of people I really was thrilled to see in the very secret proposal that you would not share with us before we went in, and then you see what all the things are that are going to happen. You are always known, though, Chaz, for being the guy. You have those little fun projects that become part of the grant that you know, live on and people are able to carry out and they've created really cool things. This proposal with the exciting AI initiatives, can you share what tools like Case, Amplify and Sara Works are going to mean for state VR agencies?   Chaz: Absolutely. And I think it's important for folks to understand the why. Right. Like, why are these it's not just because they're fun and they are super fun. You're right. But there really is a reason behind developing these projects. And the primary reason is as agencies have implemented Wioa and this kind of goes back to lessons learned, right? We know that the data elements for, for instance, for the 911 and just the recording processes and all of the administrative responsibilities associated with being in compliance with the law and the regulations is a burden. It's a struggle, and especially in a period of time where recruitment and retention has been a challenge across the country. You know, when you lose people and they're the ones responsible for gathering and reporting this data, IT becomes a real challenge on everybody else. And I honestly, in my heart of hearts, believe that embracing advanced technology is the way out of this. It's the way to effectively respond to it. It's not by hiring more people to do administrative stuff, although that would be wonderful. But, you know, we're in this situation for a reason. And now we have right now, not ten years from now, but right today we have the capacity to turn our administrative burden into an AI driven function that alleviates that burden from VR staff. And that's what the why is behind this? Why are we doing this? Because we want agencies to see and participate. If you know, if they're able and willing in these projects to see what the impact could be. Now, of course, we don't know, for instance, what the impact will fully be. We have a vision for it. But part of what this is is an experiment, right? It's a pilot, if you will, to make sure that we can see how it works. So the idea is that and I'll take Sara because Sara's been around for a while now. A lot of agencies know Sara. They know what's possible. Several of them use the program. Now, in our case, like under the VR tech, we're going to be using Sara to do something for pre-employment transition services that we haven't done yet. Now we're ten years. 11 years. Well, I guess ten years really post implementation 2016 was the full implementation. So we're approaching the ten year mark. And while we focused on implementing projects and tracking and reporting and down to the individual consumer level and all that good stuff. Making sure costs are allowable, that people are spending their 15%, all that good stuff. What we haven't done a very good job of yet is evaluating the impact of those services on individuals themselves. Like how has it impacted them? What does it mean in terms of their future employability or future involvement in post-secondary Ed or whatever it is we're trying to determine? And so using Sara specifically to communicate and gather information with students or former students on the impact of periods, and then analyzing that data and showing the impact, that's really where we're zeroed in on this project for Sara Works. Case Amplify, well let me go to CRS. So Case Review Solutions is a new software program developed by two of our former colleagues in the WINTAC and the QM, Rachel Anderson and Brittany McIvor. So they know right? Like what is it about the review system, the case review process, the process, the quality assurance process that is lacking the internal control process, right? How do we fix that or help fix it anyway? Or help states analyze where the deficiencies are and then give them information real time quickly along multiple levels to help them address it so that it's not a consistent finding and monitoring reviews so that they're on top of the changes that they need to make. So again, it's another technology solution to a challenge facing agencies. And they're also developing a contract monitoring tool that's going to be available later on in the project. That will help states monitor another big one. Right. We hear all the time is we're not sure like whether those contracts are doing what they should be doing and the quality of service delivery and all that stuff. So that's going to help with that. Case Amplify is a AI program that Intellitech has developed. It's so exciting to talk about how this could potentially change. And I mean really change the way that VR staff are gathering and populating information into the case through case management system. Ultimately, it has the capacity ultimately to make the process hands free. That is, you can talk to an individual, and this system is listening and gathering information and populating all over into the CMS important data elements, summarizing meetings. And believe it or not, like if it does what we really want it to do, it's going to actually fill in the 911 data elements automatically based on these conversations at critical points along the pathway.   Carol: That's a game changer for people that alone with those what, 400 elements like that is a game changer.   Chaz: Yeah, I could not be more excited about this one than I am. I just think it's going to be revolutionary. You know, it's still in its development phase fully. It's still going to be kind of an experiment with agencies and how it integrates into their existing CMS. But that's part of why we call it a pilot, because it's supposed to be a way to kind of see if things work the way we want it to work.   Carol: It's so cool. I am really excited. I'm also excited about the whole evaluation part of projects because I long thought, you know, when I was back in Minnesota blind and we were getting all those funds spent on students and I'm like, we're getting at these kids earlier. I just knew in my heart of hearts like, this is going to make such a difference in their trajectory is going forward and employment, they're going to start better. They're going to start better in college because they're going to have all this exposure to things they had not had any exposure to. Finally, the time we get at being able to measure, is that really coming true? I mean, I believe it to be true, but it'll be nice to actually quantify it and go, yeah, this is what's happening for people. And we can see the real difference. And that investment that Congress had said all those years ago, we're going to invest in these kids. And they did it for a reason. And now the proof is going to be in the pudding with the results. I love it. So, Chaz, one of your goals was to strengthen the workforce. So tell us a little bit about the VR Fiscal Talent Accelerator and NRLI, the National Rehabilitation Leadership Institute.   Chaz: Yeah. Great. So most people know NRLI. They've heard about it in the past and or even many participated. I remember at one point a few years ago at a conference, Steve Wooderson said, hey, how many people here have gone to NRLI. And I swear, three quarters of the room raised their hand. So it's over 20 years old now, and it's a training program specifically targeted at the executive leadership level, staff of the VR program and preparing them over a year long process where we meet in person for a week, four weeks out of the year, three times in San Diego, one time in Washington, DC. And there's coaching and training contacts that go on throughout the course of the year in a cohort model. So that is supported by the VRTAC this time around. So that's kind of our primary executive leadership training tool. Then we're developing something new this time around. For those of you who are listening, who are familiar with the management concepts training that was part of the QM, that was the VR grants management certificate program that we developed as part of that center. This time around, we are specifically zeroing in on the fiscal folks in VR and preparing a kind of like, nearly like program for them, where we'll use the same cohort model. I'm not certain of all the details yet, but obviously, Carol, you'll be a super important part of that one. And we'll provide an opportunity for fiscal staff in VR agencies who some obviously like every other position turnover at times. And when they do turnover, if they take the knowledge with them and nobody's coming behind them, it can be really challenging. So the Fiscal Talent Accelerator program will be a way to help them understand all of the responsibilities right under fiscal responsibilities in the VR grant, helping them really manage those resources and effectively so that the agency has both not just in compliance, but has the resources available to serve as many folks as possible.   Carol: Absolutely. Yeah. I'm super excited about all of these projects. We've got a lot of work ahead. I know also, we had started spending some time under the QM addressing, you know, the recruitment and retention issues and leadership development and such. So how do you see that kind of expanding in the new grant?   Chaz: Well, it's definitely expanding. And so we're very excited about that because we know clearly that recruitment and retention especially was a just a real, real issue in the last five years. So we had a recruitment and retention pilot under the QM that worked with four states. And we have some really helpful tools and toolkits developed as a result of that. That's on the QM site now, will be brought forward under the VRTAC, but more importantly will be going into phase two from that process under the VRTAC, looking again at implementing those strategies and practices for recruitment and retention with other agencies, tracking the impact of that over time, and expanding the scope of that. John Walsh was really helpful in leading that effort under the QM, and he'll be doing that again. Also, we're developing onboarding resources for VR programs this time around, helping agencies kind of identify both what to include and giving them actual stuff and resources to include in an onboarding program for VR staff. We're moving beyond just the executive level of training for nearly into mid-level management and supervisory training. Training specifically targeted at those groups, which I think will be really helpful and certainly very needed and engaging in succession planning processes with agencies, both strategic planning and succession planning understanding the two of them are clearly linked, but giving agencies some real strategies and practices on how to develop a succession plan and implement that, so that we're not faced with this sort of mass exodus of institutional knowledge. When people both retire or resign and we're like, oh no, what do we do now? Right. So hopefully we're intending to create resources, training tools to help agencies address that proactively.   Carol: And we have some really awesome staff on this grant. This time around too, that can help. Our bench is deeper. You know, even in this area that are going to be able to help do that. So definitely. Meera, you have something you want to throw in there. I didn't forget you.   Meera: Oh I don't think so. Chaz covered all the practices and new projects really well.   Carol: Okay, Meera, I want you to tackle this one about the evaluation and data driving that ongoing improvement coming forward. Do you have thoughts about that? How's that going to look?   Meera: Sure. I think I spoke to this a little bit earlier, but to pick up from that thread, I mean, that is something we are consistently doing. We have multiple channels and approaches that monitor the work and the change that are taking place. We have custom built apps and tools that our IT group has created, so we can make sure that we're setting up plans and staying on track with the agencies and the work that we're doing with them. And we have stakeholders, partners, customers, all of whom can provide feedback in different ways. We meet regularly to discuss what we are hearing and what we are seeing. Formally speaking, we have two reports that are compiled and shared broadly, internally and with stakeholders. We hold meetings, review the findings, and consider recommendations by taking that report apart and into little bite, but continuously throughout the year. We're not waiting for those big report moments. Evaluation Group has been woven into the work we do. They are a part of all the regular meetings that are taking place for the center, and input is getting provided at the beginning and the middle at the end, all over again. It really is that measurable and real change and ongoing calibration towards that is our North star. That will continue to be so.   Carol: Led by the awesome you, which will be great.   Chaz: Exactly.   Carol: My final question to you too what will success look like for the VRTAC over the next five years. And Chaz, I'll ask you first.   Chaz: Well, it will be demonstrably changing for the better outcomes in the VR program and service delivery. It will be serving individuals with the kind of commitment to meeting their individual needs and wants and desires and employment factors, and agencies operating efficiently and effectively and having actual measurable outcome improvements. So simple as that.   Carol: That sounds good. Meera, how about you? What do you think?   Meera: Nothing to add. He stole it right there at the end. Measurable outcomes. Real change. Drop the mic.   Carol: Boom! I love it. So, how do people find you?   Chaz: Our website will be VRTAC or just VRTAC.org. We have the site kind of really in its shell form right now. We're developing it. Give us a couple of months to get it fully going, but if you need to reach us, you can certainly contact any of us through the channels that you would normally reach us through the VRTAC-QM. Can send an email to me or to you or anybody else on the team. And at this point, I think most agencies are able to reach us in whatever way they want. But soon the website will be up and running and they can get us there or any number of ways.   Carol: Awesome. Well, I sure appreciate both joining me this morning. It was super cool. And we can check back in in a couple years too and go like, woo, where are things now? It'll be fun to report on some more successes. So thank you both. Have a great day.   Chaz: Thanks, Carol. Appreciate you having us.   Meera: Thank you.   Outro Voice: Conversations powered by VR. One manager at a time. One minute at a time. Brought to you by the VRTAC. Catch all of our podcast episodes by subscribing on Apple Podcasts, Google Podcasts, or wherever you listen to podcasts. Thanks for listening.

In the first episode of our "AI in Real Estate" series, Patricia Orange, CRS, joins us to explore how real estate professionals can use artificial intelligence to elevate their business without losing the personal touch that builds trust. From ChatGPT to marketing automation, Orange shares how she blends innovation with authenticity—and why staying educated and adaptable remains key in an evolving market.

This Day in Legal History: Nevada Admitted as 36th StateOn October 31, 1864, Nevada was officially admitted as the 36th state of the United States, a move driven as much by wartime politics as by the territory's readiness for statehood. With President Abraham Lincoln seeking re-election and needing support for the proposed 13th Amendment to abolish slavery, the Republican-controlled Congress saw strategic value in adding another loyal Union state. Although Nevada's population was below the threshold typically required for statehood, its vast mineral wealth and political alignment with the Union helped accelerate the process. To meet the tight timeline ahead of the 1864 election, Nevada's leaders moved quickly to draft a state constitution.Facing logistical challenges in sending the document from Carson City to Washington, D.C., Nevada officials made the unprecedented decision to transmit the entire text—over 16,000 words—via telegraph. The transmission took over 12 hours and cost more than $4,000, making it the longest and most expensive telegram ever sent at the time. The decision proved effective: the telegram reached the capital in time, and Congress formally approved Nevada's admission on the same day.The speed and cost of Nevada's telegraphic constitution became a symbol of the urgency and improvisation of Civil War-era governance. The state's motto, “Battle Born,” reflects both its literal birth during the Civil War and the political battle over slavery and Union preservation. Nevada's admission also helped secure support for Lincoln's re-election and for the 13th Amendment, which passed Congress in January 1865.In a recently disclosed legal filing, Immigration and Customs Enforcement (ICE) sought taxpayer information on over 1.28 million individuals from the IRS, though only about 47,000 records matched. The request, part of a broader effort to access data on individuals under final removal orders, was submitted under a carve-out in Section 6103 of the Internal Revenue Code, which permits limited disclosures during criminal investigations. The IRS initially rejected ICE's requests citing legal constraints, but a memorandum of understanding in April allowed for limited data sharing. A subsequent refined request from ICE in June targeted a smaller group of 1.27 million, but again, only a small percentage matched IRS records, and many failed to meet legal standards for processing.The case arose from a lawsuit filed by taxpayer advocacy groups and unions, which argue that these disclosures violate the Tax Reform Act, the Privacy Act, and the Administrative Procedure Act. Plaintiffs are seeking a preliminary injunction to halt further sharing. Internal emails reveal IRS officials were concerned about the unprecedented scale and legality of the request, and officials emphasized the need to keep the data sharing confidential. The IRS typically handles about 30,000 such data requests a year, each requiring detailed justification and high-level agency approval. Critics warn that this massive data handover poses urgent threats to taxpayer privacy and due process rights.ICE Sought Records on 1.3 Million Taxpayers, Filing Shows (1)U.S. District Judge Carl Nichols praised two federal prosecutors, Samuel White and Carlos Valdivia, for their handling of a case against Taylor Taranto, despite both being suspended by the Justice Department the day before. The suspension followed their reference to January 6 rioters as “a mob of rioters” and mention of Donald Trump allegedly sharing Barack Obama's address in a sentencing memo. Judge Nichols commended their work as professional and exemplary, stating they upheld the highest prosecutorial standards.Taranto was sentenced to 21 months in prison for firearm and hoax-related charges after being arrested near Obama's D.C. residence in 2023. However, he will not serve additional time due to pretrial detention. Though originally charged for participating in the Capitol riot, those charges were dropped under President Trump's mass clemency order for January 6 defendants issued at the start of his second term. Taranto's defense claimed his statements about explosives were meant as “dark humor” and that he hadn't committed any violence.After White and Valdivia's suspension, a revised sentencing memo—stripped of January 6 and Trump references—was filed by two replacement prosecutors, including a senior DOJ official. The incident reflects broader tensions under the Trump administration, which has repeatedly moved to minimize references to Capitol riot violence and penalize prosecutors involved in politically sensitive cases.US judge praises prosecutors who were suspended after referring to January 6 ‘mob' | ReutersA federal judge allowed the Trump administration to move forward with firing nearly all remaining employees of the Department of Justice's Community Relations Service (CRS), an agency established in the 1960s to mediate racial and ethnic conflicts. U.S. District Judge Indira Talwani, while denying a temporary restraining order sought by civil rights groups, noted that the plaintiffs failed to show immediate, irreparable harm. However, she also stated that the groups are likely to succeed in proving that the executive branch cannot lawfully dissolve a congressionally created agency.The lawsuit, brought by 11 organizations including the NAACP and the Ethical Society of Police, challenges the Justice Department's recent “reduction in force” that would leave just one CRS employee. The move follows a pattern under the Trump administration, which has rejected all new requests for CRS services and proposed no funding for the agency in its budget. Plaintiffs argue that a termination notice stating the layoffs aim to “effectuate the dissolution” of CRS confirms unlawful intent.Although Talwani's ruling allows the firings to proceed, she emphasized that the final outcome may favor the plaintiffs as the case continues. The layoffs coincide with a government shutdown that began October 1, meaning the employees would have been furloughed regardless. The DOJ claims it is merely reorganizing, not eliminating, the agency, though it concedes that only Congress has the authority to formally abolish it.Judge allows Trump administration to fire most of DOJ race-relations agency's employees | ReutersHagens Berman Sobol Shapiro, a prominent plaintiffs' law firm, is under scrutiny in two high-profile class actions, facing judicial criticism and potential sanctions. In Seattle, a federal judge sanctioned the firm for over $223,000 after finding it misled the court and opposing counsel about its client's withdrawal from an antitrust case against Apple and Amazon. The judge said Hagens Berman failed to disclose that their client, who later disappeared from proceedings, had expressed his intent to exit the case months earlier. The firm argues it acted ethically under client confidentiality rules and has asked the judge to revise her dismissal ruling.In a separate matter in Philadelphia, the firm faces possible new sanctions in long-running litigation over thalidomide-related birth defect claims. A special master found misconduct, including altering an expert report and advancing claims lacking legal merit. While Hagens Berman disputes the findings, calling them outside the master's authority and biased, U.S. District Judge Paul Diamond upheld the report. The firm has now requested that Diamond recuse himself, citing an appearance of bias due to his close coordination with the special master.In both cases, Hagens Berman maintains its actions were in good faith and within legal and ethical bounds, while critics and courts point to patterns of misrepresentation and overreach.Law firm Hagens Berman battles sanctions in Apple, thalidomide cases | ReutersThis week's closing theme is by Camille Saint-Saëns.Camille Saint-Saëns was a French composer, organist, conductor, and pianist whose long career spanned the Romantic era and touched the early 20th century. Born in Paris in 1835, he was a child prodigy who began composing at the age of three and gave his first public performance at ten. Saint-Saëns was celebrated for his extraordinary versatility, writing symphonies, concertos, operas, chamber music, and choral works. Though deeply rooted in classical forms, he was an early supporter of contemporary composers like Liszt and Wagner, even as he remained skeptical of more radical modernism. His music often combined technical brilliance with elegance, and his clear, structured style made him a bridge between tradition and innovation. He was also a prolific writer and amateur astronomer, and his intellectual breadth sometimes earned him criticism from those who found his music too refined or academic. Still, Saint-Saëns maintained influence across Europe, and his works remain staples of the concert repertoire.This week's closing theme is Saint-Saëns' Danse Macabre. Originally a song for voice and piano based on a poem by Henri Cazalis, Saint-Saëns later reworked Danse Macabre into a tone poem for orchestra. It depicts Death summoning the dead from their graves at midnight on Halloween for a wild, skeletal waltz. A solo violin—tuned unconventionally to evoke a harsh, eerie sound—plays Death's dance theme, while xylophone rattles mimic clacking bones. The piece was controversial at its premiere in 1875 but quickly became a concert favorite, especially around Halloween. With its vivid orchestration and playful macabre imagery, Danse Macabre is one of classical music's most iconic musical depictions of the supernatural, perfectly capturing the spirit of the season.Without further ado, Saint-Saëns Danse Macabre—enjoy! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Stephen Barnes, program architect of Sierra Leone's GO-FOR-GOLD residency initiative, reveals how 4,000 families will secure citizenship in 90 days – without traditional CBI legislation. Africa's fastest-growing economy chose special naturalization over citizenship by investment: What does this mean for the industry's future? Watch to discover the program parameters and why this non-CRS jurisdiction is attracting investors.Learn more about the Sierra Leone GO-FOR-GOLD program here.

Senator Ron Johnson (R-WI) joined The Guy Benson Show today to discuss the ongoing government shutdown and why Democrats are holding it hostage to score political points. Sen. Johnson criticized the nonsensical shutdown as programs like SNAP hang in the balance and hungry Americans face the fallout. Johnson explained that Republicans remain open to negotiating on health care, but Democrats continue doubling down on subsidies instead of passing a clean CR and continue negotiations. Relatedly, Sen. Johnson shared details about his new bill aimed at permanently ending government shutdowns by passing clean CRs every two weeks instead of having the government grind to a halt. Finally, Sen. Johnson weighed in on the explosive "Arctic Frost" investigation, and you can listen to the full interview below! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Viele aus unserer Community wollten wissen: Wie sicher ist mein Geld im Ausland wirklich? In dieser Folge gehe ich auf exakt 13 eurer Fragen ein – ehrlich, praxisnah und mit Beispielen aus der Realität. Was dich erwartet: • Länder, die derzeit als besonders sicher gelten? • häufige Fehler, die Anleger beim Thema Auslandskonto machen! • was du über Einlagensicherung und „Bail-in“ wirklich wissen musst! • und warum es sehr riskant ist, nur 1-2 Inlandskonten zu haben? Die Antworten könnten dich überraschen – vor allem, wenn du glaubst, dein Geld wäre auf der Bank automatisch sicher.

Este episodio es patrocinado por HalloCasa, la tarjeta de presentación digital optimizada para SEO dirigida a agentes inmobiliarios. ¿Buscas al agente adecuado sin importar dónde estés?Descubre y conecta con los mejores agentes inmobiliarios del mundo: https://home.hallocasa.com/En este episodio de HalloCasa conversamos con Alejandro Escudero, Director de Estrategia Global de la National Association of REALTORS® (NAR), la asociación inmobiliaria más grande de Estados Unidos, con presencia en más de 75 países.Hablamos sobre la misión de NAR, su presencia en América Latina, los beneficios para los miembros internacionales, cómo afiliarse desde Latinoamérica, y las certificaciones internacionales como CIPS y CRS que ayudan a elevar la carrera de cualquier agente inmobiliario.También exploramos NAR en Español, una plataforma creada para facilitar el acceso a recursos, formación y herramientas a profesionales hispanohablantes, y cerramos con consejos prácticos para quienes desean iniciar una carrera inmobiliaria.Temas destacados:00:01:00 Introducción00:04:00 Países donde opera NAR en Latinoamérica00:05:00 La misión de NAR00:11:00 Beneficios para miembros00:14:00 Cómo afiliarse desde Latinoamérica00:18:30 Certificaciones internacionales (CIPS, CRS y más)00:22:00 NAR Español: Recursos en línea00:33:00 Consejos para nuevos agentes00:36:00 Conclusión y contactoMira el episodio completo y descubre cómo llevar tu carrera inmobiliaria al siguiente nivel con NAR.Datos de Contacto:  / alejandroescuderorodriguez  https://www.nar.realtor/alejandro-esc...aescudero@nar.realtor

C'était il y a 20 ans à Clichy-sous-Bois en banlieue parisienne. Le 27 octobre 2005, Zyed Benna, 17 ans, et Bouna Traoré, 15 ans, mouraient électrocutés après avoir été pourchassés par la police. Les adolescents s'étaient réfugiés dans un transformateur EDF pour tenter d'échapper à un contrôle d'identité. Le drame avait déclenché 21 nuits d'affrontements entre jeunes et forces de l'ordre en banlieue parisienne d'abord, puis partout en France. Des révoltes qui ont permis aux habitants de ces quartiers populaires de montrer les discriminations qu'ils vivaient au quotidien, sur le plan social, mais aussi géographique. 20 ans plus tard, RFI est retourné à Clichy-sous-Bois. Si les infrastructures de la ville se développent (le métro y fera d'ailleurs son arrivée en 2027), le poids de l'histoire tragique de Zyed et Bouna pèse toujours sur les Clichois. Depuis 2019, c'est un peu plus facile d'aller et venir à Clichy-sous-Bois, même si, à 15 kilomètres seulement de Paris, la ville reste mal desservie par les transports en commun. C'est ici que Mehdi Bigaderne a grandi. Il avait 23 ans en 2005 : « J'étais à l'université de Saint-Denis, je mettais trois heures, alors peut-être qu'on met un peu moins, je ne sais pas, aujourd'hui, mais on met quand même beaucoup de temps et, effectivement, on ne part pas de la même ligne de départ, ça, c'est certain. Et cette question des discriminations, elle n'est pas vraiment prise au sérieux. » Ce tramway, le T4, avait pourtant été annoncé en personne par le président Jacques Chirac dès 2006, au lendemain des violences urbaines, nées ici, dans un quartier fragile, mais tranquille, qui s'est brutalement retrouvé sous le feu des projecteurs : « Je m'en souviens comme si c'était hier, parce que c'est tellement marquant. Je suis un enfant de la ville et c'est la première fois que je voyais la ville dans cet état-là, avec des brigades de CRS pratiquement dans chaque immeuble. Et puis, après, on a vu arriver un hélicoptère – moi, j'avais l'impression d'être à Bagdad, à un moment donné – qui tournait autour des immeubles avec un projecteur, qui était pénétrant dans les appartements, déjà qu'ils n'étaient pas très grands… » À écouter aussiBanlieues 2005 : retour à Clichy-sous-Bois La mort de Zyed et Bouna a laissé des cicatrices profondes dans le quartier À l'époque, l'ampleur de la réponse sécuritaire choque les habitants qui pleuraient deux enfants du quartier : Zyed Benna, 17 ans, et Bouna Traoré, 15 ans. Ce qui n'arrange rien au rapport fragile entre police et population… Olivier Klein, maire actuel, était adjoint à la jeunesse et à la ville il y a 20 ans : « Quand les maires de l'époque ont vu le président de la République, il a demandé quelles seraient les urgences. Les deux maires, ensemble, ont dit : "Il nous faut un tramway – une des raisons de la popularisation, c'est l'enclavement, le temps pour aller bosser, le temps pour aller étudier, etcetera –, et on a besoin d'avoir un commissariat de plein exercice – pour que la police puisse être comme un poisson dans l'eau dans nos quartiers". » À lire aussiFrance: il y a 20 ans, la mort de Zyed Benna et Bouna Traoré à Clichy-sous-Bois Les discriminations, un enjeu majeur En 2012, un commissariat sort de terre à Clichy. Les cicatrices sont encore bien visibles, mais d'après Mehdi Bigaderne, qui a cofondé l'association ACLEFEU pour faire remonter la parole des quartiers populaires auprès des institutions, constate que les choses changent petit à petit : « Les commissaires qui ont dirigé ce commissariat étaient ouverts à travailler avec les associations, donc on voyait qu'il y avait une volonté de se dire, s'il y a des incidents, on peut s'en parler… En revanche, je pense qu'ils sont limités parce que, je ne crois pas me tromper en disant ça, c'est qu'on a aussi un problème qui est plutôt général. Moi, je suis content de pas avoir revécu un tel drame sur la ville, mais il y en a eu d'autres malheureusement, et il faut que l'État prenne à bras-le-corps ce sujet-là qui, aujourd'hui, peut être un fonds de commerce pour certains politiques. » En 20 ans, les visages enfantins de Zyed et Bouna ont été rejoints par des dizaines de sourires similaires dans les marches blanches. D'après le média Basta!, le nombre de décès annuels imputables aux forces de l'ordre françaises a doublé depuis les années 2000. À lire aussiIl y a dix ans, les banlieues s'embrasaient dans toute la France

This episode is brought to you by HalloCasa, the SEO-ranked digital business card for real estate agents. Looking to find the right agent, no matter where you are?Visit https://home.hallocasa.com to discover and connect with top real estate agents globally.In this episode of HalloCasa, we speak with Alejandro Escudero, Director of Global Strategy at the National Association of REALTORS® (NAR), the largest trade association worldwide with over 1.5 million members.Alejandro shares valuable insights into NAR's international initiatives, the Global Ambassador and Coordinator programs, and the importance of understanding local real estate ecosystems around the world.He also discusses global certifications such as CRS and CIPS, clarifies the difference between real estate brokers and REALTORS®, and highlights emerging trends in global real estate, proptech, and international collaboration.If you're a real estate professional looking to expand globally, understand international standards, or connect with REALTORS® worldwide, this episode is for you.Timestamps:00:01:00 Introduction00:02:00 National Association of REALTORS®00:08:30 Global Ambassadors and Coordinators Program00:09:30 Understanding Local Culture, Legal Systems, and Markets00:13:30 REALTORS® vs Brokers and Professional Standards00:16:30 Global Certifications: CRS and CIPS00:19:30 Real Estate Trends, NAR's REACH Program & Proptech00:23:30 Common Challenges and Misconceptions of Associations00:25:30 Tips to Succeed as a Real Estate Agent00:32:30 Conclusion and Final WordsContact Information:  / alejandroescuderorodriguez  https://www.nar.realtor/alejandro-esc...aescudero@nar.realtor

This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications.Topics Covered1. SMOLDERING MULTIPLE MYELOMALINKER-SMM1Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration.Discussion Points:Appropriateness of 2-year treatment duration for precursor conditionEfficacy and MRD-negative ratesSafety considerations in asymptomatic populationPatient selection if available today2. NEWLY DIAGNOSED MULTIPLE MYELOMAMajesTEC-5Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance.Discussion Points:Post-induction MRD-negativity rates with Tec-DR and Tec-DVRGrade 3-5 infection rates and infection-related deathsQuestionable utility of bortezomib and need for ASCT with 100% MRD-negativityHigh infection prophylaxis requirementsMagnetisMM-6Phase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years).Discussion Points:VGPR or better ratesSafety profile including infections and CRS/ICANSRisk of continuous therapy in elderly/frail populationLINKER-MM4Phase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant-ineligible pathways, exploring three dose levels (50, 100, 200 mg).Discussion Points:Efficacy of single-agent Linvo in NDMMWhether any NDMM population could achieve long-term control with single-agent BCMA BsAbSafety profile3. RELAPSED/REFRACTORY MULTIPLE MYELOMACAMMA-1Phase 1b randomized dose-expansion study of cevostamab (FcRH5×CD3 bispecific) combined with pomalidomide-dexamethasone in BCMA-naïve patients with median 2 prior lines of therapy.Discussion Points:Efficacy and safety resultsPositioning in treatment paradigmUse before BCMA BsAbs?Sonrotoclax + Dexamethasone in t(11;14) R/R MMPhase 1/2 study of sonrotoclax (next-generation BCL2 inhibitor) plus dexamethasone as an all-oral regimen in patients with t(11;14) R/R MM (median 3 prior lines, ~75% triple-exposed).Discussion Points:Efficacy including response rate and PFSSafety profileFuture of BCL2 inhibitors in t(11;14) myeloma in the era of BsAbs and CAR TRedirecTT-1Phase 2 trial combining teclistamab + talquetamab in 90 heavily pretreated patients with R/R extraosseous extramedullary disease (84% triple-class refractory, 36% penta-refractory, 20% prior BCMA CAR T).Discussion Points:Response rate and durability in difficult-to-treat populationSafety concerns with dual bispecific combinationOff-label use considerations4. CAR T-CELL THERAPY TOXICITIESCAR T Immune-Related Adverse Events (UPenn Study - Ho et al)Large cohort study of 198 patients (125 cilta-cel, 73 ide-cel) examining all adverse events other than CRS, ICANS, IEC-HS, and IECAHT.Discussion Points:Landscape of CAR T IRAEs: incidence, types, and timingRisk factors identified for CirAEsMechanism of toxicities and role of CD4+ CAR T-cellsClinical implications: Should prophylactic corticosteroids be used? What ALC threshold? Optimal dose/duration? Prospective studies needed?

Éste episodio es patrocinado por HalloCasa, la tarjeta de presentación digital optimizada para SEO dirigida a agentes inmobiliarios. ¿Buscas al agente adecuado sin importar dónde estés?Descubre y conecta con los mejores agentes inmobiliarios del mundo: https://home.hallocasa.com/En este episodio de HalloCasa #236, converso con Dulce Punaro, asesora inmobiliaria certificada de RE/MAX Metrópoli en la Ciudad de México.Dulce nos comparte su visión sobre el mercado inmobiliario en el Centro-Sur de la CDMX, los retos de la gentrificación, los derechos de inquilinos y propietarios, y consejos clave para compradores, vendedores e inversionistas.También hablamos sobre su certificación CRS (Certified Residential Specialist), su experiencia en RE/MAX Global, y su propio método “Paso a Paso”, diseñado para lograr transacciones seguras, sin estrés y con acompañamiento humano.Temas del episodio:00:01:00 – Introducción00:04:40 – La situación inmobiliaria del Centro-Sur de la Ciudad de México00:10:30 – Gentrificación en la CDMX00:15:20 – Derechos de arrendadores e inquilinos00:20:00 – Cómo trabaja RE/MAX en México y a nivel global00:24:00 – Consejos para inversionistas inmobiliarios00:26:00 – Qué es CRS y su importancia00:28:00 – Tendencias del mercado inmobiliario en la CDMX00:30:00 – El método “Paso a Paso” de Dulce Punaro00:39:00 – Conclusión y formas de contactoConecta con Dulce Punaro:  / dulcepunaro    / dulcepunaro  https://hallocasa.com/profile/6308

What's a Government Shutdown and Why Are We In One?A government shutdown happens when Congress fails to pass annual spending bills or a stopgap continuing resolution (CR) to keep agencies funded. No funding = no authority to operate = federal workers furloughed, services paused, and chaos for agencies and contractors.The House has passed a CR that would fund the government through November 21, but the Senate has rejected it three times. That CR keeps spending at current levels and buys Congress more time to negotiate a full budget. Think of it as saying, “We'll work out the details later, but in the meantime, keep the lights on.”So why the rejection? The sticking points are:* Democrats want the bill to include an extension of Affordable Care Act (ACA) subsidies, which are about to expire.* They also want to block the Office of Management and Budget (OMB) from continuing to cut previously appropriated funds—something they see as a power grab.* Senator Rand Paul is the only Republican joining Democrats in opposing the House CR, but most Senate Democrats have voted it down.What Has to Happen to End the Shutdown?There are four main steps to reopening the government:* Negotiate a compromise CR. Either Republicans agree to ACA and OMB language, or Democrats back off.* Secure bicameral agreement. If the Senate changes the bill, it has to go back to the House.* Presidential approval. Trump has hinted he won't sign anything that includes ACA subsidies or limits on the OMB.* Implementation. Once signed, agencies resume normal operations and furloughed workers return.Two likely paths out of the shutdown:* Republicans stand firm → Democrats allow a CR vote without ACA or OMB demands, hoping to negotiate later.* A compromise CR is passed → includes ACA subsidies and OMB limits → enough Senate Democrats back it → risk of Trump veto remains.Why Is This So Complicated?The shutdown highlights a procedural gap between the House and Senate:* In the House, Republicans have a majority and can pass CRs with zero Democratic votes.* In the Senate, most bills need 60 votes to end debate (invoke cloture) and move to a final vote. Republicans don't have the numbers.Republicans could try to change Senate rules—eliminate the filibuster for budget bills and go with a simple majority—but that would be a massive institutional shift with long-term consequences.Until a resolution is reached, the government remains partially closed and the policy fight over ACA funding and executive power continues.What Happens If Republicans Do Make the Change?If Senate Republicans decide to invoke the so-called “nuclear option”—changing the chamber's rules to eliminate the 60-vote threshold for spending bills—the legislative and political landscape could shift immediately and dramatically.Immediate consequences:Republicans could pass the House-approved continuing resolution with no Democratic support, reopening the government on their terms. That means no extension of ACA subsidies, no restrictions on the Office of Management and Budget, and no need to negotiate across the aisle.Medium-term effects:The rule change would permanently alter how Congress handles appropriations. Any party with a Senate majority and House control could pass funding bills unilaterally, sidestepping the need for bipartisan coalitions. This could speed up the process—but also deepen partisan divides in budget negotiations.Long-term implications:Effectively, it would mean the end of the filibuster for all spending legislation. Shutdowns might become less frequent, since fewer votes are needed to keep the government open—but funding priorities could swing wildly every time control of Congress changes hands. One Congress could expand programs and hike spending; the next could cut deeply, all with a simple majority.In short, while the nuclear option would solve the immediate standoff, it would reshape the Senate's role in fiscal policymaking—and shift power further toward the majority party.Why Can't Republicans Just Pass a Budget Bill?If you've been hearing people say, “Just pass it as a budget bill—no filibuster needed,” here's why that's not happening.The Senate does have a special process called budget reconciliation, which allows certain bills to pass with just 51 votes—no filibuster, no 60-vote threshold. But there are some important catches:* It can only be used once per fiscal year.Technically, reconciliation instructions can cover three areas—spending, revenue, and the debt limit—but Congress usually combines them into a single package. That bill has already been used this year (for the “One Big Beautiful Bill Act”), so the reconciliation tool is off the table until the next fiscal year.* The content of the bill is strictly limited.Under the Byrd Rule, reconciliation bills must directly relate to taxing or spending. Any provision that doesn't have a direct budgetary effect, or that increases the deficit beyond a 10-year window, gets stripped out—or the whole bill risks being disqualified.That's why the current CR probably couldn't go through reconciliation even if that option remained available this fiscal year. It likely includes provisions that violate the Byrd Rule—and certainly would if the OMB limitation Democrats want was included. Those elements either aren't strictly budgetary or would impact the long-term deficit.So even though Republicans hold a Senate majority, they can't simply slap a “budget” label on this bill and pass it with 51 votes. That procedural door is closed for now.If they want to bypass the filibuster, their only real option would be to change Senate rules—a dramatic move that would eliminate the 60-vote requirement for spending bills altogether. Otherwise, they'll need to cut a deal that clears the 60-vote threshold—or accept a prolonged shutdown.That is the current state of the shutdown – we'll see you back here on Monday for our usual daily news shows. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Kim Strassel, Potomac Watch columnist for the Wall Street Journal, Fox News Contributor, and author of The Biden Malaise: How America Bounces Back from Joe Biden's Dismal Repeat of the Jimmy Carter Years, joined The Guy Benson Show today to break down Chuck Schumer's government shutdown and why it is directly hurting broad swaths of government workers while giving Vought and the Trump admin an opening for mass firings. Strassel explained why the "collective insanity" of the left has led Democrats to abandon their stance on clean CRs, and how the move is really about coddling the far left so Schumer has a message to run on when facing possible primary challenges. Strassel and Benson also broke down why the assassination of Charlie Kirk is now being used by universities as an excuse to shut down right-wing speech under the guise of "security concerns." Listen to the full interview below! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Show #1120 And Again... ...too late and all brand new. 01. Downtown Mystic - Somebody's Always Doin' Something To Somebody (3:54) (Mystic Highway, Sha-La Music, 2025) 02. Miss Emily – Stand Together, Band Together (5:24) (Medicine, Gypsy Soul Records, 2025) 03. Scott Low - Goin' Down the Road Feelin Bad (2:30) (Grateful Blues, self-release, 2025) 04. Dave Weld & the Imperial Flames - Red Hot Tabasco (3:06) (Bluesin' Through The Years, Delmark Records, 2025) 05. Bob Augustine - I'm In Love (3:28) (Folk-IndieBob, MTS Records, 2025) 06. Bob Corritore & Little Milton - I Want To Be The One (3:37) (Early Blues Sessions, SWMAF/VizzTone Records, 2025) 07. Levi Platero - Lay It Down (4:02) (Leaving This Town, self-release, 2025) 08. Shirley Johnson - Blues Attack (4:29) (Selfish Kind Of Gal, Delmark Records, 2025) 09. Manu Lanvin - Change My Ways (4:57) (Man On A Mission, Gel Production, 2025) 10. Gwyn Ashton - Down & Dirty (3:50) (Grease Bucket, Fab Tone Records, 2025) 11. Billy Branch & The Sons Of Blues - The Harmonica Man (5:47) (The Blues Is My Biography, Rosa's Lounge Records, 2025) 12. Spencer Mackenzie - What You Do (4:28) (Empty Chairs, Gypsy Soul Records, 2025) 13. Dallas Burrow (ft. Ray Wylie Hubbard) - Read 'Em and Weep (3:10) (The Way The West Was Won, Forty Below Records, 2025) 14. LaBek - Seek And Ye Shall Find (4:24) (Trouble Blues, self-release, 2025) 15. Randy Lee Riviere - On My Way Down (4:11) (Farmhand Blues, Wilderness Records, 2025) 16. The Soul Of John Black - Been Gone Too Long (3:45) (Soul Salvation, Yellow Dog Records, 2025) 17. Little Hat - Jelly Jam (3:14) (Rocking This Joint Tonight, CRS, 2025) 18. Bywater Call - Hold Me Down (3:20) (Single, self-release, 2025) 19. Jay Hooks - My Kinda Fine (3:04) (Tequila & Bullets, Joplin Street Records, 2025) 20. Ana Popovic - California Chase (3:28) (Dance To The Rhythm, Electric Heel Records, 2025) 21. Jim Keller - Black Dog (4:02) (End Of The World, Continental Song City, 2025) 22. Mick Clarke - Walking In The Dark (3:32) (Tell The Truth, BGO Records, 1991) Bandana Blues is and will always be a labor of love. Please help Spinner deal with the costs of hosting & bandwidth. Visit www.bandanablues.com and hit the tipjar. Any amount is much appreciated, no matter how small. Thank you.

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “Phase 1 Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-like T-Cell Engager Obrixtamig in Patients with DLL3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results of Obrixtamig in patients with DLL3+ small cell lung cancer and neuroendocrine carcinomas. In this study, 168 patients were treated with Obrixtamig across four different dosing regimens. 49% of the patients had small cell lung cancer, 42% had extrapulmonary neuroendocrine carcinoma, and 8% had large cell neuroendocrine carcinoma of the lung. Patients received a median of two prior lines of therapy. 33% of the patients had brain metastases at baseline. Of note, this trial did not mandate baseline brain imaging. Maximum tolerated dose was not reached. 88% of the patients experienced a treatment-related adverse event, however, only 3.6% of the patients had to discontinue treatment due to treatment-related AEs, and dose reduction due to treatment-related AEs was documented in 2.4% of the patient population. Similar to the other DLL3-targeted bi-therapies, the most common adverse events included CRS in 57%, dysgeusia in 23%, and pyrexia in 21% of the patients. CRS events were mostly mild. They occurred more frequently in the first two to three doses. 9% of the patients experienced ICANS, of which 3% were graded as Grade 3 or higher. And let's review the efficacy results. Responses were only seen in patients who received 90 microgram per kg or more once weekly or once every three weeks dosing. The objective response rate in patients who received an effective dose was 28%. If we review by tumor type, 21% of the small cell lung cancer patients, 27% of the extrapulmonary neuroendocrine carcinoma patients, and 70% of the large cell neuroendocrine carcinoma patients had objective response. Median duration of response was 8.5 months, though this data is immature due to short follow-up. Dr. Wermke, DLL3-targeted bispecific T-cell engagers are reshaping the treatment landscape of small cell lung cancer. This trial investigates Obrixtamig in other high-grade neuroendocrine tumors as well. Can you put this trial into context for us and explain why it may represent an important step forward? Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to discuss our data today. I think the data with Obrixtamig in small cell lung cancer are largely similar to what has been observed with other bispecific T-cell engagers such as tarlatamab with respect to the response rate and duration. It has, however, been to be mentioned that BI 1438001 had a bit more liberal inclusion criteria than other trials around. You already mentioned the fact that we allowed the inclusion of patients without mandatory brain imaging, which led to some patients having their brain mets been diagnosed during the treatment with obrixtamig and then adding to the progressive disease patients. That is something which was not the case with the tarlatamab trials where you really had to have a brain imaging before, and in the Phase 1 trial you were even required to treat the brain mets before you included the patient. So it is a bit different, more poorest patient population. I think the trial adds on existing data by being the first trial to also include non-SCLC neuroendocrine carcinoma of other origin, for example from the gastrointestinal tract, and also by including large cell neuroendocrine carcinoma of the lung, which is a really hard to treat pulmonary neoplasm which currently lacks any standardized treatment. So that is really a step forward which we will build on in the future. Dr. Ece Cali: And one thing I would note in this trial, only patients with tumor expressing DLL3 were enrolled. Can you tell us a little bit more about this target, DLL3 in the context of neuroendocrine tumors, and does DLL3 expression predict clinical outcomes after treatment with DLL3 BiTEs, or do we actually need other predictive biomarkers for these novel agents? Dr. Martin Wermke: Yeah, thank you. That's a pretty interesting question. First of all, DLL3 is an atypical notch ligand, which is expressed by the majority of neuroendocrine carcinomas, virtually absent on healthy adult tissues. Therefore, turning it really into a bona fide target for T-cell engaging therapies, pretty low risk for on-target off-tumor side effects. We found that in all the patients we screened, we had an expression rate of about 94% in small cell lung cancer, 80% of large cell neuroendocrine carcinoma of the lung were positive, and also about 80% of the extrapulmonary neuroendocrine carcinoma. So it's really a high prevalence. So the fact that we only included DLL3+ tumors still means we included most of the patients that presented with these diseases. I think at the moment there are no data suggesting a clear-cut association between DLL3 expression levels and outcome on DLL3 CD3 T-cell engagers. There's also not a lot published. If you want to find this out for tarlatamab, you have to look into their patent to really see the data, but it's not clear-cut and I'm sure we need other markers to complement that. And I think what probably plays a major role is intrinsic T-cell fitness. So the question how really diseased your T-cells are, how old you are, because age also correlates with the fitness of the immune system, and other patient characteristics such as tumor burden, we've seen all across the board that the higher the tumor burden, the lower the rate of prolonged response is in such trials. And I also think we need to focus on other components of the tumor microenvironment. So see how high the T-cell infiltration with obrixtamig is and how abundant suppressive elements like regulatory T-cells or myeloid-derived suppressive cells are. That is work which is currently being done. Data are emerging, but I don't think that at the moment we have any clear biomarker helping us to select who should not receive DLL3 T-cell engagers. Dr. Ece Cali: Those are great points and there is a lot we need to learn about how to use these novel agents in the future. I'd like to highlight the results in large cell neuroendocrine carcinoma of the lung. The response rate in this group was remarkably high at 70%. Though we should note the small sample size of only 14 patients in this trial. After first line chemoimmunotherapy, current approved options for this population have very modest clinical activity. Given these trial results, how do you envision the field moving forward for patients with large cell neuroendocrine carcinoma? Dr. Martin Wermke: Yeah, I think LCNEC is really an area which urgently needs further improvement of therapeutic standards. At the moment, as I said, there is no real standard. We are usually extrapolating from results we have in small cell lung cancer or non-small cell lung cancer, but I don't think we have too many prospective trials really informing this. Of course, 14 patients is a small sample size, but I think it's still fair to say that we can claim that DLL3 T-cell engagers are not doing worse in LCNEC than they do in SCLC. And that's why I think we really need to move forward clinical trials that are specifically targeting this population. Although I fear a bit that, given the rareness of this disease and the aggressiveness of its phenotype, that this is probably not the main focus of the pharmaceutical industry. So I think it's up to us academic investigators to really come up with investigator-initiated trials trying to fill the knowledge gaps we have here. Dr. Ece Cali: And one more thing that I want to talk about is the accessibility for these drugs. These novel agents are showing real promise in improving outcomes for patients with high-grade neuroendocrine tumors, an area where progress has been limited until very recently. However, as DLL3 BiTEs become more widely used, issues of logistics and access come into sharper focus. With unique toxicities and the specialized monitoring, their use is restricted to certain centers. Looking ahead, what kinds of strategies could help mitigate some of these adverse events or make these treatments more broadly available? Dr. Martin Wermke: Yeah, I think if you look at countries like the United States where tarlatamab has already been approved, we can see how the management strategies are evolving. I've heard about a colleague equipping their patients with thermometers and a pill of Dexamethasone, alongside with a temperature control protocol and clearly instructing them, "If you measure a temperature above a certain level then start taking the Dexamethasone and come back to our office and we're going to take care of you." I think that's one way to move forward. I think we are lucky in a way that CRS usually manifests within the first 24 hours. This was the same in our study, like in the tarlatamab studies. So we really know when the time of trouble is for our patients. And in this time, I think we need to instruct the patients to stay close to the hospital. I don't think we need to hospitalize all of them, but we probably need them to stay in a nearby hotel to be able to reach the emergency room if needed in a short period of time. And I think we can also learn in this strategy how to manage bispecific antibodies from the experience our colleagues in hematology had because they have been using bispecific T-cell engagers for quite some years right now and they developed strategies and networks that were able to successfully treat these patients also on an outpatient basis. And I think that is clearly an experience we need to follow, acknowledging that we are talking about diseases which are much more frequent than the standard hematology indications. Dr. Ece Cali: Thank you so much, Dr. Wermke, for this informative discussion and for sharing your perspective on this evolving field. Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to talk about data. It was really great being able to share that, and I really think that we are just at the beginning of a new exciting area for the treatment of neuroendocrine carcinomas, and I think much improvement is yet to come for our patients. Dr. Ece Cali: Yes, that's really exciting. And thank you everyone for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Martin Wermke's Disclosures Honoraria: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer,  BMS GmbH & Co. KG, Regeneron, MJH/PER, Takeda Consulting or Advisory Role: Bristol-Myers Squib, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, immatics, Bayer, ImCheck therapeutics, AstraZeneca, Tacalyx, Regeneron, Daiichi Sankyo Europe GmbH, Zymeworks, PharmaMar, Iovance Biotherapeutics, T-Knife, Genentech Research Funding: Roche Patents, Royalties, Other Intellectual Property Travel, Accommodations, Expenses: Pfizer, Bristol-Myers Squibb, AstraZeneca,  Amgen,  GEMoaB, Sanofi/Aventis, immatics,  Merck Serono, Janssen Oncology, Iovance Biotherapeutics, Daiichi Sankyo Europe GmbH"

Looking for daily inspiration?  Get a quote from the top leaders in the industry in your inbox every morning.   What's the one premier event that brings the global attractions industry together? IAAPA Expo 2025, happening in Orlando, Florida, from November 17th through 21st. From breakthrough technology to world-class networking and immersive education, IAAPA Expo 2025 is where you find possible.  And, just for our audience, you'll save $10 when you register at IAAPA.org/IAAPAExpo and use promo code EXPOAPROSTEN. Don't miss it — we won't!   Ron Romens is the President of Commercial Recreation Specialists (CRS). A lifelong creator and entrepreneur, he's been a welder, butcher, truck driver, concession operator, inventor, founder of RAVE Sports (where he helped introduce the first floating trampoline), and, since 1999, the leader of CRS. From Verona, Wisconsin, CRS has grown to approximately 60 team members, representing dozens of top-tier product lines and offering end-to-end recreation solutions—designing lakes and beaches, curating aqua parks, splash pads, shade, and more for camps, municipalities, attractions, and resorts. In this interview, Ron talks about unstructured play, controlling your experience, and how boredom stimulates creativity. Unstructured play “To me, I think unstructured play, I don't think there's near enough of it nowadays. Everything we have is very structured.” Ron ties his inventor mindset directly to the freedom he experienced outdoors as a kid—“sleeping under the stars, swinging off the rope swing, turning over rocks, catching crawdads.” Those unscripted days formed a template for how CRS designs experiences today: create spaces that invite discovery, not dictate it. Whether it's a floating trampoline evolved into a “floating playground” or a purpose-built lake with active and passive zones, CRS builds environments where guests can self-organize, collaborate, and learn through play. He contrasts this with more static, linear attractions (“chlorine and concrete”), noting that open-water, back-to-nature settings put “grass and sand between people's toes.” The result is cross-generational connection and replayability—like the multigenerational family he watched at a Whoa Zone, all choosing their own challenges and sharing one big, memorable experience together. Controlling your experience “People want to have a little bit more control of their own experience now.” Ron traces a market shift since the late 2000s from passive, ride-centric theming toward participatory recreation—zip lines, ropes courses, and on-water challenge parks where guests set pace, path, and intensity. CRS leans into this demand by curating “best-of-class” equipment and tailoring it to each client's goals—amenity, program tool, or monetized attraction—so guests can choose routes, repeat obstacles, or team up with family members. This philosophy extends to CRS's consulting approach: before selling gear, they back up to the “why.” Who is the audience? What outcomes matter? How will success be measured over one, three, and five years? By aligning design with desired control (from gentle exploration to vigorous challenge), CRS helps owners deliver experiences that feel personal, social, and repeatable. Boredom stimulates creativity “It also gets you into a place where you might even have some boredom. And boredom kind of stimulates creativity as well, especially when you've got a group of kids together.” For Ron, occasional boredom is a feature, not a bug. In nature, what first seems disorderly reveals patterns the longer you stay. Give kids a bucket, shovel, sand, and water and “they'll be there forever… creating new games.” CRS intentionally designs canvases—dynamic lakes, floating courses, beaches—where conditions (wind, water, temperature, crowd mix) change daily, nudging guests to tinker, adapt, and invent. That dynamism inspires the “human spirit,” a core CRS mission. Like skiing after fresh snow versus on ice, the same aqua park feels new each visit. Guests return not just for equipment, but for the open-ended possibilities it unlocks—play that sparks imagination, collaboration, and confidence.   In closing, you can learn more about Commercial Recreation Specialists at crs4rec.com or contact Ron directly at 877-896-8442. This podcast wouldn't be possible without the incredible work of our faaaaaantastic team:   Scheduling and correspondence by Kristen Karaliunas   To connect with AttractionPros: AttractionPros.com AttractionPros@gmail.com AttractionPros on Facebook AttractionPros on LinkedIn AttractionPros on Instagram AttractionPros on Twitter (X)

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamabMonitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamigPresenters: Dr Christopher Flowers Division Head, Division of Cancer MedicineChair, Professor, Department of Lymphoma/MyelomaJohn Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer MedicineMD Anderson Cancer CenterHouston, TexasDr John AllanAssociate Professor of Clinical MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

durée : 00:03:33 - Charline explose les faits - par : Charline Vanhoenacker - 29 sociétés de journalistes alertent sur une nouvelle atteinte à la liberté d'informer. Cet été, le ministère de l'Intérieur a donné pour instruction à la police de ne pas tenir compte du statut de journaliste en cas de “violences urbaines”. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

(The Center Square) – With 26 days until the federal government runs out of money, top appropriators have narrowed in on their preferred funding gameplan: push the equivalent of the Senate's three-bill minibus through the House, then let a Continuing Resolution temporarily cover the rest. Approving a CR would mark the fourth time in a row that U.S. lawmakers have punted on funding the government properly, having passed three CRs in fiscal year 2025 to keep government funding essentially on cruise control. Congress is supposed to craft and pass 12 appropriations bills on an annual basis, providing updated funding for federal agencies to spend on programs.Support this podcast: https://secure.anedot.com/franklin-news-foundation/ce052532-b1e4-41c4-945c-d7ce2f52c38a?source_code=xxxxxxFull story: https://www.thecentersquare.com/national/article_89a16630-f91a-4610-b832-b0cb77b1fc6a.html

Jana Kramer, the actress, singer, podcast host, and mother joins us to pull back the curtain on the entertainment industry's less glamorous realities and share how she's found her authentic voice through it all.Jana's story begins with remarkable determination – handing her headshot to a soap opera actor while waitressing in Detroit, then convincing a casting director she lived in New York to land her first role. This fearlessness carried her through roles on Friday Night Lights and One Tree Hill before an unexpected pivot to country music during a writers' strike revealed another dimension of her talent.What makes Jana's perspective so refreshing is her willingness to acknowledge both her strengths and limitations. "I don't have the Carrie Underwood voice," she admits, explaining how she instead leaned into emotional authenticity and stage presence. This honesty extends to her candid revelations about industry politics – from being told her CRS performance caused single failures to restrictions on her acting career while pursuing music. Her observations about women in country radio illuminate persistent gender disparities that continue despite the success of predecessors like Faith Hill and Shania Twain.Beyond career insights, Jana opens up about personal growth through therapy, the challenges of balancing touring with Dancing with the Stars competition, and finding joy in her current focus on acting and podcasting. Her experience hosting multiple weekly podcast episodes echoes our own journey – navigating when to speak candidly versus holding back, and finding purpose in connecting with listeners despite occasional backlash.Whether you're a longtime fan from her One Tree Hill days, discovered her through country radio hits like "I Got the Boy," or are new to her story, Jana's resilience and multifaceted career offer inspiration for anyone navigating creative industries while staying true to themselves. Listen now to this conversation that feels less like an interview and more like friends catching up over coffee – or perhaps a bottle of wine, as Jana would prefer.The Try That in a Small Town Podcast is powered by e|spaces! Redefining Coworking - Exceptional Office Space for Every BusinessAt e|spaces, we offer more than just office space - we provide premium private offices designed for focus and growth. Located in the heart of Music Row, our fully furnished offices, private suites, meeting rooms and podcast studio give you the perfect space to work, create and connect. Ready to elevate your business? Book a tour today at espaces.comFrom the Patriot Mobile studios:Don't get fooled by other cellular providers pretending to share your values or have the same coverage. They don't and they can't!Go to PATRIOTMOBILE.COM/SMALLTOWN or call 972-PATRIOTRight now, get a FREE MONTH when you use the offer code SMALLTOWN.Original BrandsOriginal brands is starting a new era and American domestic premium beer, American made, American owned, Original glory.Join the movement at www.drinkoriginalbrands.comFollow/Rate/Share at www.trythatinasmalltown.com -Browse the merch: https://trythatinasmalltown.com/collections/all -For advertising inquiries, email info@trythatinasmalltown.comThe Try That In A Small Town Podcast is produced by Jim McCarthy and www.ItsYourShow.co

Dive into the intricacies of Iranian Nuclear Power with Kenneth Katzman. Find out more about whether Iran has nuclear bombs, what Russia's role is and whether Russia even plays a role, what Iran's strategic motivations could be, the implications and consequences of the US and Israel's military actions, whether there are Iranian opposition groups, and more!Dr. Katzman is a Senior Advisor at the Soufan Group and a Senior Fellow at the Soufan Center, positions he assumed after retiring in late 2022 from his longtime position as a Senior Middle East Analyst at the Congressional Research Service (CRS). He is also a Senior Research Advisor at the Global Insights Group's Strategic Analysis and Situational Awareness Group. During his CRS career specialising on Iran, U.S. sanctions on Iran, the Arab Gulf states, Iraq, Afghanistan, and Iran-backed regional armed groups, Katzman provided analysis and advice to members of Congress through tailored reports and briefings. On about a dozen occasions, he has testified before various Committees and Subcommittees of Congress. He also participated in numerous congressional delegations to the region at the Member and staff level. During 1996 and again during July 2001 - March 2002, he was assigned to the majority staff of the House Foreign Affairs Committee to work on Middle East issues, organizing hearings and helping to draft legislation such as the Iran Sanctions Act (1996).As a well-known expert on the region, Dr. Katzman has delivered numerous presentations and briefings at conferences and meetings in Washington as well as throughout Europe, Asia, the Middle East, and South and Central Asia. In 1998, he wrote expert working papers on the ballistic missile capabilities of Iran and Iraq for the Commission to Assess the Ballistic Missile Threat to the United States ("Rumsfeld Commission"). In late 1999, and again in 2010, the Atlantic Council published his detailed monographs on U.S. sanctions on Iran. During his CRS career and since retiring, Katzman has been quoted frequently on the region and appeared in many regional media, including Al Jazeera, Al Hurra, Al Arabiya, Asharq News, Al Arabiy, and Al Ghad TV. He has authored articles for organizations including The Atlantic Council, the Gulf International Forum, the Arab Gulf States Institute in Washington, and the Arab Center D.C. He has served on several think-tank working groups and been a consultant to several corporations.The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime, to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter. The International Risk Podcast – Reducing risk by increasing knowledge.Follow us on LinkedIn and Subscribe for all our updatesTell us what you liked!

In this episode Harriet and Grahame discuss the recent OECD Report Taking Stock of Progress on Transparency and Exchange of Information for Tax Purposes. The report attempts to take stock of the successes and weaknesses of the international tax information exchange regime. Harriet and Grahame discuss whether the report succeeds and analyse the data within it. Amongst all that they have a slight frolic off into a discussion of whether or not the CRS always applied to crypto currency and whether the fast approaching Crypto Asset Report Framework was really necessary.You can find the report here:https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/07/taking-stock-of-progress-on-transparency-and-exchange-of-information-for-tax-purposes_cf7047a4/afddc8c5-en.pdf

Dans cette édition :Israël déçu par la reconnaissance française d'un État palestinien prévue en septembre à l'ONU, l'ambassadeur israélien critiquant une "soumission de la France à une idéologie inquiétante".La France, l'Allemagne et le Royaume-Uni s'apprêtent à envoyer des aides humanitaires à Gaza, dans un contexte de tensions diplomatiques.Actes antisémites condamnés à Toulouse et Marseille, avec des inscriptions menaçantes et une agression d'une humoriste juive.Déploiement de la CRS 8 à Tourcoing pour tenter de ramener le calme après une série de fusillades.Alerte de Santé publique France sur la hausse des passages aux urgences liés à la consommation de cocaïne.Projet de révision constitutionnelle pour accorder plus d'autonomie à la Corse, un sujet épineux pour le gouvernement.Progression modérée du PIB français au deuxième trimestre, dans un contexte économique incertain.Nouvelles frappes russes en Ukraine, malgré les menaces de sanctions de Donald Trump.Hommage au chanteur Ozzy Osbourne, leader du groupe Black Sabbath, dans sa ville natale de Birmingham.Bons résultats des nageurs français aux championnats du monde de natation à Singapour.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Effroi à Tourcoing avec trois fusillades la semaine dernière sur fond de trafic de drogue, la CRS 8 spécialisée dans le maintien de l'ordre a été déployée pour gêner délinquants et trafiquants et rassurer les habitants inquiets.Nouveau règlement de compte à Marseille lié au trafic de stupéfiants, une voiture de police percutée après un refus d'obtempérer et des policiers visés par des jets de projectiles.Le ministre de la Justice Gérald Darmanin présente son projet de réforme pénale visant à réintroduire du bon sens dans le fonctionnement de la justice, avec notamment la suppression du sursis à répétition et le rétablissement des courtes peines de prison.Un cinquième corps retrouvé dans les décombres d'un foyer pour personnes en situation de handicap incendié en Charente.L'Union Européenne s'engage à acheter pour 750 milliards de dollars d'hydrocarbures américains sur 3 ans, une dépendance qui inquiète.La France, l'Allemagne et le Royaume-Uni vont livrer une aide humanitaire à Gaza et pourraient reconnaître un État palestinien.Un nouvel acte antisémite à Toulouse, le Conseil constitutionnel valide la loi contre l'antisémitisme à l'université.Coup de froid sur la Méditerranée avec des températures anormalement basses pour la saison.Le quadruple champion olympique Léon Marchand se qualifie pour les demi-finales du 200m 4 nages, Tadej Pogacar fait l'impasse sur le Tour d'Espagne.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Youtube Video of podcast Shownotes and Links In this episode adamd and Zardus chat with Jeff Huang, Ze Sheng, and Qingxiao Xu from the AIxCC team all_you_need_is_a_fuzzing_brain about their AIxCC final submission. We discuss the innovative use of an AI-focused approach in their CRS. The conversation also highlights the significance of static analysis, performance metrics, and the future of cyber reasoning systems in the context of ongoing advancements in AI. We discuss the importance of local models, strategies for vulnerability detection, and the complexities of patching. Links OS lab

In this episode of Better Edge, Bruce K. Tan, MD, discusses the newest clinical practice guidelines for the surgical management of chronic rhinosinusitis (CRS). Dr. Tan covers how treatment paradigms have evolved over the past 15 years, from antibiotic-centric approaches to multifaceted strategies that recognize CRS as a complex inflammatory condition. He dives into the guidelines' recommendations on diagnoses, biologic therapies and multidisciplinary collaboration. Additionally, Dr. Tan shares insights on future directions for research and the promise of precision medicine in tailoring effective treatments for a range of patient profiles.

In part 2 of our series on gender equality in road races we sit down with Canada Running Series CEO and TCS Toronto Waterfront Marathon race director Charlotte Brookes. After noticing a sharp drop off in female marathon participation post-pandemic, Charlotte and her team at CRS set out to address the decline, with the aim of bringing more gender parity to starting lines across CRS events. At the heart of their initiative has been their "Women's Training Program"  in partnership with Mile2Marathon, offering a free 16-week training plan to all female participants in the marathon and half-marathon events at Toronto Waterfront.Now in it's second year, the program has seen participation quadruple since it's inception in 2024 and with it a growing community of motivated female participants supporting one another on their journey to the finish line this October 19th. Tune in this week to hear more about the work Charlotte and her team at CRS are doing as well as how her own experience as a new mother and runner has given her wider perspective on the needs of female athletes. You can find part 1 of our series here. Thanks to this week's sponsor Altitude Sports. Shop now at Altitude Sports and enjoy up to 20% off your first order with the promo code “shakeout” Click here to order

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and platelets under arterial shear conditions. Investigators say it's a novel biophysical mechanism that potentially contributes to post-vaccination arterial thrombosis. Finally, we explore lineage switch, an emerging form of acute leukemia relapse with dismal outcomes. It arises rapidly following antigen-targeted immunotherapy, highlighting the importance of advanced methods for detection and treatment.Featured Articles: Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 studyShear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosisProject EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Dans Europe 1 Matin :Invités : Frédéric Ploquin, grand reporter, spécialiste du grand banditisme et auteur du livre "Les réseaux secrets de la police" et Franck Allisio, député Rassemblement National des Bouches du RhôneLes forces de l'ordre tentent d'enrayer le fléau des violences urbaines à Béziers avec le déploiement de la CRS 80 en renfort pour lutter contre le trafic de drogue dans le quartier de la Devez.17 narcotrafiquants parmi les plus dangereux de France passent leur première nuit dans la prison de haute sécurité de Vendin-le-Vieil, un établissement hors normes destiné à accueillir 100 détenus à risque d'ici début août.Le ministre de l'Intérieur Bruno Retailleau durcit le ton et retire les privilèges diplomatiques à 80 dignitaires algériens accusés d'avoir dénigré la France, dans le cadre de la riposte graduée contre l'Algérie.Un Français sur cinq dort moins de 6 heures par nuit, le ministre de la Santé Yannick Neuder annonce 25 préconisations pour lutter contre cette dette de sommeil généralisée.Valentin Paret-Peintre offre la première victoire française sur le Tour de France en s'imposant au sommet du mythique Mont Ventoux, une performance historique.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Les forces de l'ordre tentent de reprendre le contrôle face aux violences urbaines à Béziers, avec le déploiement de la CRS 81 pour lutter contre le trafic de drogue dans la ville.Les 17 premiers narcotrafiquants les plus dangereux de France ont été transférés dans la nouvelle prison de haute sécurité de Vendin-le-Vieil, sous haute surveillance.Le ministre de la Justice justifie la mise en place de ce dispositif carcéral exceptionnel pour lutter contre le narcotrafic et la criminalité organisée.En France, l'absentéisme au travail atteint des niveaux record, poussant le gouvernement à envisager des réformes du système d'indemnisation des arrêts maladie.Valentin Paret-Peintre, un coureur français, remporte une victoire historique sur le mythique Mont Ventoux lors du Tour de France.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Les forces de l'ordre sont mobilisées à Béziers pour lutter contre le trafic de drogue dans un quartier gangréné par ce fléau, avec le renfort de la CRS 81 qui mène des opérations de fouille dans les logements suspects.17 narcotrafiquants parmi les plus dangereux de France ont été transférés dans la prison de haute sécurité de Vendin-le-Vieil, sous un dispositif sécuritaire hors norme, le ministre de la Justice justifiant ces mesures face à la menace du narcotrafic.Le couple franco-allemand affiche son unité malgré des divergences, notamment sur les questions de défense, l'Allemagne poursuivant ses achats d'armements américains tandis que la France souhaite une Europe plus souveraine.La France exige plus de fermeté de l'Union Européenne dans les négociations avec les États-Unis, menaçant de représailles face à la possibilité de surtaxes douanières.Les États-Unis se retirent de l'UNESCO, accusant l'organisation de promouvoir des causes clivantes et d'être partiale envers Israël, une décision qui s'inscrit dans la politique de retrait de plusieurs agences onusiennes.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Retour au calme précaire dans le quartier de la Devez à Béziers après des émeutes liées au trafic de drogue, grâce à l'intervention d'une unité de CRS spécialisée dans la lutte contre les violences urbaines.Transfert de 17 narcotrafiquants particulièrement dangereux vers la prison ultra-sécurisée de Vendin-le-Vieil, dans le cadre d'un plan visant à regrouper 100 détenus à risque dans une véritable forteresse carcérale.Sanctions du ministre de l'Intérieur Bruno Retailleau contre des dignitaires algériens ayant dénigré la France, dans un contexte de tensions diplomatiques entre les deux pays.Inquiétude des habitants de Béziers quant au départ annoncé des renforts policiers, craignant le retour des trafiquants de drogue.Dégradation de la qualité du sommeil des Français, avec un Français sur cinq dormant moins de 6 heures par nuit, selon les recommandations des experts.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Plusieurs débats au cœur de l'actualité, les Grandes gueules ont le choix, en débattre ou non : 180 300 euros à des CRS, Mbappé soupçonné de pots de vin Bientôt le droit de vote à 16 ans au Royaume-Uni ! 29 ans, âge moyen pour un premier enfant en France

Send us a textDo you have CRS like we do?We might have gotten heat stroke, but you still got your episode! Daniel forgets Dr. Jones and Marcus can't remember anything. Wear protective clothing to protect you from the sun's harmful rays. Support the show

7/1/25 6am CT Hour - Mark Mastroianni/ Art Wigchers John and Sarah chat about Big Beautiful Bill, conviction of Idaho murderer, US Postage Stamps and holiday travel. Mark breaks down where AI is going next and Pope Leo's guidelines for ethics when it comes to tech. Art shares how he became involved with CRS and the education of girls in Ethiopia. https://crs.donordrive.com/girlsgain

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

中国人民银行与香港金融管理局于6月20日联合宣布，内地与香港快速支付系统互联互通（下称跨境支付通）将于6月22日正式上线。届时，两地居民仅凭收款方手机号码或银行账户，即可完成小额跨境汇款的实时到账操作，突破传统跨境汇款的时效限制。 当前，首批参与跨境支付通共12家，其中内地机构包括工、农、中、建、交五家国有大行以及招商银行；香港机构包括中银香港、东亚银行、建银亚洲、恒生银行、汇丰香港、工银亚洲，后续将逐步扩大参与范围。 02:13 跨境支付通：6月22号后的转账变革，速度与手续费的双重颠覆！ 05:26 招行和交行的转账体验对比：方便快捷但有限额 10:53 在四大上班，每个月给女儿汇款一万元生活费，养儿育女的现实与劝退 16:23 “信用卡额度限制：生活使用与投资之间的尴尬选择” 21:49 揭开CRS的神秘面纱：中国税务机关如何掌握境外信息 27:16 揭秘FATCA：美国与中国之间的双向信息交换机制 32:48 香港银行卡与人民币支付的便利性：在内地和香港之间的无缝连接 38:16 海外投资的机遇与挑战：普通百姓如何实现资产增值？ 43:42 创业者的必备心态：百万大火 Origin Story 49:10 A股投资策略：技术分析、基本面分析与基本面认知的重要性 54:39 投资理念与经历：在旅途中寻找优质股票的故事 01:00:04 情绪价值与实际收益：理财中的幻觉与现实差距

中国人民银行与香港金融管理局于6月20日联合宣布，内地与香港快速支付系统互联互通（下称跨境支付通）将于6月22日正式上线。届时，两地居民仅凭收款方手机号码或银行账户，即可完成小额跨境汇款的实时到账操作，突破传统跨境汇款的时效限制。 当前，首批参与跨境支付通共12家，其中内地机构包括工、农、中、建、交五家国有大行以及招商银行；香港机构包括中银香港、东亚银行、建银亚洲、恒生银行、汇丰香港、工银亚洲，后续将逐步扩大参与范围。 02:13 跨境支付通：6月22号后的转账变革，速度与手续费的双重颠覆！ 05:26 招行和交行的转账体验对比：方便快捷但有限额 10:53 在四大上班，每个月给女儿汇款一万元生活费，养儿育女的现实与劝退 16:23 “信用卡额度限制：生活使用与投资之间的尴尬选择” 21:49 揭开CRS的神秘面纱：中国税务机关如何掌握境外信息 27:16 揭秘FATCA：美国与中国之间的双向信息交换机制 32:48 香港银行卡与人民币支付的便利性：在内地和香港之间的无缝连接 38:16 海外投资的机遇与挑战：普通百姓如何实现资产增值？ 43:42 创业者的必备心态：百万大火 Origin Story 49:10 A股投资策略：技术分析、基本面分析与基本面认知的重要性 54:39 投资理念与经历：在旅途中寻找优质股票的故事 01:00:04 情绪价值与实际收益：理财中的幻觉与现实差距

The Community Relations Service was created by the Civil Rights Act to smooth out race relations during desegregation, but like every government agency, it quickly took on a life of its own. The shadowy organization has an incredible level of secrecy and pushes woke agendas, including the normalization of trans kids and the planting of mosques in all Christian towns. Worst of all, the CRS is known to compel grieving families who are the victims of minority crime to deliver prepared statements downplaying the violence of their attackers. Academic Agent joins me to discuss.  Follow on: Apple: https://podcasts.apple.com/us/podcast/the-auron-macintyre-show/id1657770114 Spotify: https://open.spotify.com/show/3S6z4LBs8Fi7COupy7YYuM?si=4d9662cb34d148af Substack: https://auronmacintyre.substack.com/ Twitter: https://twitter.com/AuronMacintyre Gab: https://gab.com/AuronMacIntyre YouTube:https://www.youtube.com/c/AuronMacIntyre Rumble: https://rumble.com/c/c-390155 Odysee: https://odysee.com/@AuronMacIntyre:f Instagram: https://www.instagram.com/auronmacintyre/ Learn more about your ad choices. Visit megaphone.fm/adchoices